AR: Sanofi-Aventis is notifying healthcare professionals about updated safety information for the antidepressant Norpramin, which is desipramine hydrochloride. The section on overdosage now notes that overdoses of this drug have resulted in a higher death rate than overdoses of other tricyclic antidepressants.
MB: Also, a new warning in the labeling now says to use extreme caution when giving this drug to patients with a family history of sudden death, cardiac dysrhythmias, and cardiac conduction disturbances. The warning also notes that in some patients, the cardiac dysrhythmias and death were preceded by seizures. For more information, go to our website.

标题
New Warnings on Norpramin (FDA)

视频介绍
FDA Patient Safety News - February, 2010 - Show #95
Sanofi-Aventis is notifying healthcare professionals about updated safety information for the antidepressant Norpramin, which is desipramine hydrochloride.

Speaker #1:: Anita Rayner (AR), Associate Director, Policy & Communications, U.S. Food and Drug Administration

Speaker #2:: Mark Barnett (MB), Assistant Director, Education & Communication, U.S. Food and Drug Administration